Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects

MeSH terms

• Aged
• Alemtuzumab
• Antibodies, Monoclonal / administration & dosage*
• Antibodies, Monoclonal / adverse effects
• Antibodies, Monoclonal, Humanized
• Antibodies, Neoplasm / administration & dosage*
• Antibodies, Neoplasm / adverse effects
• Genes, p53*
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
• Leukemia, Lymphocytic, Chronic, B-Cell / genetics
• Male
• Methylprednisolone / administration & dosage*
• Methylprednisolone / adverse effects
• Middle Aged